Pamiparib in mCRPC With HRD or BRCA1/2 Mutation

• Status: Recruiting
• Trial end date: 2025-03-20

Summary

The purpose of this study is to assess the efficacy of a PARP inhibitor, Pamiparib, in metastatic castration-resistant prostate cancer patients with homologous recombination deficiency or BRCA 1 or 2 somatic/germline mutation.

• Phase: Phase 2

Details

• Lead Sponsor: Sun Yat-sen University